Libevitug Approved in China as First-in-Class Treatment for Hepatitis D

2026-01-27 - 09:36

BEIJING, Jan. 27, 2026 /PRNewswire/ — Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of the large envelope protein of